Sodium chlorite. EV FL500ML 3MEQ ML
Active ingredient SODIUM CHLORIDE INTRAVENOUS ADDITIVE SOLUTIONS therapeutic
Group Product Type
GENERIC DRUG MAKES NO SSN scheme
Class C Type Recipe OSP
Form Farm. INJECTIONS container BOTTLE
Validity Date Commerc 36 months. 01/12/2005
ATC B05XA03
Producer Price Monica Spa
Pharmacotherapeutic
ADDITIVE intravenous solutions. INDICATIONS
The solution 'referred to as exogenous sodium and chlorine in the course of
Total Parenteral Nutrition (TPN) in adult and pediatric
and in which' established a deficiency of these ions in response to excessive
or diuresis to excessive salt restriction.
CONTRAINDICATIONS / EFF.SECONDAR
In patients with hypernatremia. Pregnancy and lactation. Give
and only if clearly needed '.
DOSAGE The dosage of sodium chloride and 'established on the basis of the age' of p
eso, clinical conditions, electrolyte balance and acid bas
and patient. The dosage and 'then according to requirements met
abolish the patient identified on the basis of laboratory data and clinical evaluation of
. The product should be used exclu sively
as a solution to be added to mixes for the NPT. Tratt
asi a concentrated solution for which and not 'planned chief
direct administration only after dilution in a large volume of fluid
.
INTERACTIONS
Please refer the user to the scientific literature.
SIDE EFFECTS
hypervolemia or symptoms associated with a deficiency or an excess of one or more
'ions in the solution. Excessive administration of sodium
can 'cause hypernatremia and high cloridremia can' cause
bicarbonate loss with acidifying. Febrile responses, tr
Ombos venous phlebitis. In case of adverse reaction stop s
omministrazione and uphold the
not given for any examinations. The patient 'called for tell your doctor or pharma cist
any side effects not listed in this leaflet
TiVo. Use immediately after opening the container. The solution should be
clear, colorless and free of visible particles.
need for a single, uninterrupted administration and any residue can not '
be used. Do not inject as such but only after appropriate d
iluizione and mixing. Use with great caution in patients co
n congestive heart failure, severe renal insufficiency and in stat
clinicians and edema associated with salt and water retention;
t reatment in patients with corticosteroid drugs and corticotrophin. Monitors the budget are
fluids, electrolytes, osmolality '
plasma and acid-base balance.
Permanent Works Of Viola Tiziana Massa - St. Gabriel The Archangel Church-Palermo
Thursday, March 17, 2011
Landing Strip Brazilian Wax
KCL SODIUM CL 0.9 0.3 3.8 50F 20SAC
Active POTASSIUM CHLORIDE / SODIUM CHLORIDE
Group therapeutic intravenous solutions
Product Type GENERIC DRUG MAKES NO SSN scheme
Class C Type Recipe OSP
Form Farm. INJECTIONS container BOTTLE
Validity Date Commerc 36 months. 01/02/2007
ATC B05BB01
Producer Price BAXTER SpA
MECHANISM OF ACTION
electrolyte. INDICATIONS AND
'used for the prevention and treatment of potassium depletion
and / or hypokalemia in conditions involving a loss of
the sodium chloride and water.
CONTRAINDICATIONS
E 'used for the prevention and treatment of potassium depletion
and / or hypokalemia in conditions involving a loss of
the sodium chloride and water. Serum levels of hyperkalemia and lead to my ipocale
impairment 'heart of the heart is
maternal fetal. So 'maternal electrolyte levels should be monitored regularly
. When used for appropriate
cations and then at the therapeutic dose administration of the product can
or 'be possible during pregnancy and lactation.
SIDE EFFECTS Adverse reactions may be due the technique somminis
traction. These include febrile response, infection at the site of the
nfusione, local pain or reaction, vein irritation, venous thrombosis or phlebitis
extending from the infusion site, extravasation and IPervoice
Olema. In the case of side effects, the infusion should be discontinued
a. The drug 'a hypertonic solution with an osmolarity' approximate
mativa of 388 mOsm / l. The administration should be carried out under
regular and careful monitoring. Regular monitoring of clinical s
Committee, the concentration of plasma electrolytes, the
ivelli of serum creatinine, BUN level dell'equilibio
olite and electr ECG and 'fundamental in patients undergoing treatment on c
potassium, particularly those who have heart failure or renal
. We must ensure that the urine flow is adequate and must be monitored
and fluid balance. The potash was
should be administered with caution in patients with considerable pain
Attie or cardiac conditions that predispose to hyperkalemia, c ome
renal or adrenal insufficiency, acute dehydration, or extensive tissue destruction
as that seen in burns gra
do severe. required regular monitoring of potassium levels molded
us in patients under therapy with digitalis. Sodium salts
should be administered with caution in patients with hypertensive
one, heart failure, peripheral or pulmonary edema, functionality
to 'impaired kidney, pre-eclampsia, or other conditions associated with the intention of re
sodium.
INTERACTIONS
Solutions containing potassium should be used with caution n
and patients treated with drugs that increase serum potassium concentrations
(for example, potassium-sparing diuretics,
ACE inhibitors, angiotensin II receptor antagonists, ciclos
porin Tacrolimus and drugs that contain potassium).
Corticosteroids are associated with the retention of sodium and water, resulting in
and edema and hypertension.
DOSAGE AND METHODS 'recruitment
Adults, elderly and children: The dose may be expressed in mEq or mmol per
anion per cation, the mass of each cation, or mass of c ach
salt cation. For the NaCl 1g Sodium = 394 mg or 17.1 mEq Na + or
17.1 mmol of Na + and Cl-, Na + 1 mmol = 23 mg Na +. For potassium. 1d
K Cl = 525 mg K + or 13.4 mEq or 13.4 mmol of K + and Cl-, 1 mmol K + K + = 39.1 mg
. The dosage depends on age ', by weight, condition
clin ic and organic (acid-base balance) of the patient,
to concomitant therapy, and particularly the state of hydration of patients
e. GENERAL DOSAGE. Recommended dosage for the treatment of depletion
isotonic fluids (extracellular dehydration) through
or any intravenous solution. Adults: from 500 ml to 3 liters, or 24
king for infants and children: 20 to 100 ml per 24 hours and
pes per kg or body, according to age 'and the total body weight.
DOSAGE FOR THE PREVENTION AND TREATMENT potassium depletion. The doses of potassium
typically used to prevent dell'ipopot
together can we reach 50 mmol per day, and similar doses may be indicated in
mild potassium deficiency. The maximum dose recommended potassium
mum and '2 to 3 mmol/Kg/24 hours. When
zzato useful for the treatment of hypokalemia
and the recommended dose 'of 20 mmol of potassium within 2-3 hours (eg 7-10
mmo l / h) under monitoring by ECG. The rate 'infusion Max wheel
recommended to not exceed 15-20 mmol / h Patients with renal insu
fficienza should receive lower doses. However, in every c
Aso, the recommended dosage should not be exceeded. SOMMINISTRAZION
E. The administration is performed intravenously using u
n'attrezzatura sterile and nonpyrogenic. Potassium must 'be somminis
trato intravenously using a large peripheral vein or
eral cent to reduce the risk sclerosis. If the solution is infused into a central vein
, make sure that the catheter is not located in the atrium or the ventricle
to avoid hyperkalaemia localizzat
a. Solutions containing potassium should be given
slowly. Speed \u200b\u200b'infusion. Intravenous administration of potassium
should not exceed a rate 'infusion of 10-20
them mmo / time to avoid dangerous hyperkalemia. Monitoring. NECE
xed verify that the urine flow is adequate and is' essential
accurately monitor the plasma concentrations of potassium and other electrolytes
. High doses or high speed 'of infusion and should
be monitored by ECG.
Active POTASSIUM CHLORIDE / SODIUM CHLORIDE
Group therapeutic intravenous solutions
Product Type GENERIC DRUG MAKES NO SSN scheme
Class C Type Recipe OSP
Form Farm. INJECTIONS container BOTTLE
Validity Date Commerc 36 months. 01/02/2007
ATC B05BB01
Producer Price BAXTER SpA
MECHANISM OF ACTION
electrolyte. INDICATIONS AND
'used for the prevention and treatment of potassium depletion
and / or hypokalemia in conditions involving a loss of
the sodium chloride and water.
CONTRAINDICATIONS
E 'used for the prevention and treatment of potassium depletion
and / or hypokalemia in conditions involving a loss of
the sodium chloride and water. Serum levels of hyperkalemia and lead to my ipocale
impairment 'heart of the heart is
maternal fetal. So 'maternal electrolyte levels should be monitored regularly
. When used for appropriate
cations and then at the therapeutic dose administration of the product can
or 'be possible during pregnancy and lactation.
SIDE EFFECTS Adverse reactions may be due the technique somminis
traction. These include febrile response, infection at the site of the
nfusione, local pain or reaction, vein irritation, venous thrombosis or phlebitis
extending from the infusion site, extravasation and IPervoice
Olema. In the case of side effects, the infusion should be discontinued
a. The drug 'a hypertonic solution with an osmolarity' approximate
mativa of 388 mOsm / l. The administration should be carried out under
regular and careful monitoring. Regular monitoring of clinical s
Committee, the concentration of plasma electrolytes, the
ivelli of serum creatinine, BUN level dell'equilibio
olite and electr ECG and 'fundamental in patients undergoing treatment on c
potassium, particularly those who have heart failure or renal
. We must ensure that the urine flow is adequate and must be monitored
and fluid balance. The potash was
should be administered with caution in patients with considerable pain
Attie or cardiac conditions that predispose to hyperkalemia, c ome
renal or adrenal insufficiency, acute dehydration, or extensive tissue destruction
as that seen in burns gra
do severe. required regular monitoring of potassium levels molded
us in patients under therapy with digitalis. Sodium salts
should be administered with caution in patients with hypertensive
one, heart failure, peripheral or pulmonary edema, functionality
to 'impaired kidney, pre-eclampsia, or other conditions associated with the intention of re
sodium.
INTERACTIONS
Solutions containing potassium should be used with caution n
and patients treated with drugs that increase serum potassium concentrations
(for example, potassium-sparing diuretics,
ACE inhibitors, angiotensin II receptor antagonists, ciclos
porin Tacrolimus and drugs that contain potassium).
Corticosteroids are associated with the retention of sodium and water, resulting in
and edema and hypertension.
DOSAGE AND METHODS 'recruitment
Adults, elderly and children: The dose may be expressed in mEq or mmol per
anion per cation, the mass of each cation, or mass of c ach
salt cation. For the NaCl 1g Sodium = 394 mg or 17.1 mEq Na + or
17.1 mmol of Na + and Cl-, Na + 1 mmol = 23 mg Na +. For potassium. 1d
K Cl = 525 mg K + or 13.4 mEq or 13.4 mmol of K + and Cl-, 1 mmol K + K + = 39.1 mg
. The dosage depends on age ', by weight, condition
clin ic and organic (acid-base balance) of the patient,
to concomitant therapy, and particularly the state of hydration of patients
e. GENERAL DOSAGE. Recommended dosage for the treatment of depletion
isotonic fluids (extracellular dehydration) through
or any intravenous solution. Adults: from 500 ml to 3 liters, or 24
king for infants and children: 20 to 100 ml per 24 hours and
pes per kg or body, according to age 'and the total body weight.
DOSAGE FOR THE PREVENTION AND TREATMENT potassium depletion. The doses of potassium
typically used to prevent dell'ipopot
together can we reach 50 mmol per day, and similar doses may be indicated in
mild potassium deficiency. The maximum dose recommended potassium
mum and '2 to 3 mmol/Kg/24 hours. When
zzato useful for the treatment of hypokalemia
and the recommended dose 'of 20 mmol of potassium within 2-3 hours (eg 7-10
mmo l / h) under monitoring by ECG. The rate 'infusion Max wheel
recommended to not exceed 15-20 mmol / h Patients with renal insu
fficienza should receive lower doses. However, in every c
Aso, the recommended dosage should not be exceeded. SOMMINISTRAZION
E. The administration is performed intravenously using u
n'attrezzatura sterile and nonpyrogenic. Potassium must 'be somminis
trato intravenously using a large peripheral vein or
eral cent to reduce the risk sclerosis. If the solution is infused into a central vein
, make sure that the catheter is not located in the atrium or the ventricle
to avoid hyperkalaemia localizzat
a. Solutions containing potassium should be given
slowly. Speed \u200b\u200b'infusion. Intravenous administration of potassium
should not exceed a rate 'infusion of 10-20
them mmo / time to avoid dangerous hyperkalemia. Monitoring. NECE
xed verify that the urine flow is adequate and is' essential
accurately monitor the plasma concentrations of potassium and other electrolytes
. High doses or high speed 'of infusion and should
be monitored by ECG.
Subscribe to:
Posts (Atom)